This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2581-2584, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates of Mycobacterium tuberculosis†

Yuzhi Dong, Xilin Zhao, Barry N. Kreiswirth, and Karl Drlica*

Public Health Research Institute, New York, New York 10016

Received 16 August 1999/Returned for modification 1 October 1999/Accepted 19 June 2000


    ABSTRACT
Top
Abstract
Text
References

The mutant prevention concentration (MPC) of a C-8-methoxy fluoroquinolone exhibited a narrow distribution for 14 genetically diverse clinical isolates of Mycobacterium tuberculosis, indicating that results from single-isolate studies are likely to be representative. When one isolate was challenged with a variety of antituberculosis agents, C-8-methoxy fluoroquinolones were exceptional in having MPCs below the maximum concentration attained in serum by use of commonly recommended doses.


    TEXT
Top
Abstract
Text
References

Antibiotic resistance is becoming an increasingly serious problem for many bacterial diseases (12). To help halt further selection of resistant mutants, we have defined a drug concentration threshold above which bacterial cells require the presence of two or more resistance mutations for growth (20). The simultaneous occurrence of multiple mutations is a rare event relative to the number of cells present during infection; consequently, administration of antibiotic above the concentration threshold, which we call the mutant prevention concentration (MPC), should severely restrict selection of resistant mutants. Experimentally, MPC has been taken as the drug concentration that allows no mutant to be recovered from a susceptible population of more than 1010 cells (7). For MPC to be therapeutically useful, it must be below the concentration achievable in serum or tissue with safe doses of antibiotic. Whether such situations exist has not been determined.

In earlier work we found that addition of a methoxy group to the C-8 position of N-1-cyclopropyl fluoroquinolones makes the compounds particularly effective against quinolone-resistant mutants of Escherichia coli (13, 22), Staphylococcus aureus (7, 21), Mycobacterium bovis BCG (6, 7), and Mycobacterium tuberculosis (19). For M. bovis BCG the MPC of a C-8-methoxy fluoroquinolone was only 12% of that observed of its C-8-hydrogen derivative or a clinical standard, ciprofloxacin (7). Thus, C-8-methoxy fluoroquinolone attack of a pathogenic mycobacterium could provide a good experimental system for determination of whether MPC can be lower than the serum drug concentration.

In the present study we measured the susceptibilities of 14 M. tuberculosis isolates to PD161148, the fluoroquinolone that had previously been shown to have the most activity against mycobacteria, to determine whether diverse isolates respond to fluoroquinolones in the same general way. Test isolates with different IS6110 DNA types were chosen (18). To minimize potential bias, we studied several clinical isolates from each of the three main genetic groups of M. tuberculosis (16). As an additional geographical test we examined strains collected from both the United States and Russia. We then chose one isolate, an outbreak strain from New Jersey (3), to compare the abilities of several new C-8-methoxy fluoroquinolones (Fig. 1) and conventional antituberculosis agents to restrict the selection of resistant mutants.


View larger version (27K):
[in this window]
[in a new window]
  		FIG. 1.   Fluoroquinolone structures.

Clinical isolates of M. tuberculosis were cultured as described previously (6). The MIC was determined by plating dilutions of cultures on 7H10 agar plates containing various concentrations of antibiotic (6). The concentration that reduced the number of colonies recovered by at least 99% relative to the number of untreated control colonies recovered was taken as the MIC. For mutant selection, cultures were grown to the stationary phase in liquid medium, concentrated by centrifugation (3,000 × g for 10 min), resuspended in fresh 7H9 medium (10), and applied in various amounts to agar plates containing different concentrations of antibacterial agent. More than 1010 CFU was plated for the highest antibiotic concentrations (>2 × 109 CFU to each of five agar plates). Colonies were counted after incubation at 37°C for 4 weeks, and they were retested for growth on drug-containing agar plates to confirm that they were resistant mutants.

Increasing the quinolone concentration caused colony recovery to decline sharply and then level to a plateau (Fig. 2). A concentration was reached for the C-8-methoxy compound (PD161148) at which no mutant was recovered when more than 1010 cells were applied to agar plates (arrowhead on abscissa of Fig. 2). A plot of the plateau region using a linear scale, shown as an inset in Fig. 2, illustrates restriction of mutant selection by the C-8-methoxy compound under conditions in which mutant colonies were readily recovered with its C-8-H derivative, PD160793. Similar curves were obtained for all 14 strains, although in a few cases it was necessary to extrapolate linear plots (Fig. 2, inset) to estimate the MPC. The MPCs of PD161148 ranged from 1 to 4 µg/ml, with the MPC being 1 to 3 µg/ml for 85% of the isolates (Table 1). The narrow range of MPCs indicates that measurement of MPC is likely to be useful for comparison of the potencies of fluoroquinolones against diverse isolates of M. tuberculosis.


View larger version (29K):
[in this window]
[in a new window]
  		FIG. 2.   Effect of fluoroquinolone concentration on selection of resistant mutants. M. tuberculosis isolate TN7804 was applied to agar plates containing the indicated concentrations of PD161148 (C-8-methoxy; open circles) or PD160793 (C-8-H; filled circles). After incubation, the number of drug-resistant colonies was recorded and plotted relative to the number of CFU applied to the drug-free agar plates. The arrowhead indicates the drug concentration at which no colony was recovered from plates containing C-8-methoxy fluoroquinolone when more than 1010 cells were applied. (Inset) Data for points where the fraction of cells recovered was below 10-7, replotted using a linear scale.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Effect of the C-8-methoxy fluoroquinolone PD161148 against clinical isolates of M. tuberculosis

The average MIC of PD161148 was approximately 0.2 µg/ml (Table 1), which was about half that observed for PD160793 (data not shown). For isolates for which MICs were low, MPCs tended to be low. Neither the MIC nor the MPC displayed a relationship with the genotypic group or the IS6110 DNA polymorphism type.

To compare antituberculosis agents for the ability to restrict selection of mutants, we recovered resistant mutants at a variety of concentrations of different drugs using M. tuberculosis strain TN6515, a pan-susceptible isolate of the W4 IS6110 DNA type (3). Mutation frequency was a complex function of drug concentration (Fig. 3). The several inflection points observed with isoniazid (Fig. 3A) and streptomycin (Fig. 3C) suggest that different resistance alleles may dominate at different antibiotic concentrations. This prediction is being tested. For ciprofloxacin (Fig. 3D), we showed previously that many different alleles are selected and that the abundance of any particular resistance allele depends on the drug concentration (22a).


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 3.   Effect of antituberculosis agent concentration on selection of resistant mutants. M. tuberculosis isolate TN6515 was applied to agar plates containing the indicated concentrations of isoniazid (A), rifampin (B), streptomycin (C), and ciprofloxacin (D). After incubation, the number of drug-resistant colonies was recorded and was plotted relative to the number of CFU applied to drug-free agar plates.

The MPCs of standard antituberculosis agents and C-8-methoxy fluoroquinolones were estimated by plating more than 1010 cells on drug-containing agar and determining the concentration that allowed recovery of no colony (Table 2). These data show that MPC determinations are not limited to fluoroquinolones. However, for rifampin, streptomycin, and kanamycin we failed to find concentrations that prevented the recovery of mutants; for these compounds we obtained only minimum estimates of MPCs. Table 2 also lists the maximum concentrations of the commonly recommended doses of each compound achieved in serum. The concentrations of traditional antituberculosis agents in serum failed to exceed the MPCs; consequently, these compounds will select resistant mutants whenever they are administered as monotherapy (8, 20). In contrast, the C-8-methoxy fluoroquinolones moxifloxacin and PD135432 (gatifloxacin) had MPCs below the maximum concentration achievable in serum (Table 2).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Potencies of anti-tuberculosis agents against M. tuberculosisa

The data described above indicate that tuberculosis may be treatable with C-8-methoxy fluoroquinolones at concentrations that will severely restrict the selection of resistant mutants. It may be possible to develop an effective dual-drug therapy by combining one of the C-8-methoxy fluoroquinolones with another antituberculosis drug: when the concentrations of both compounds are kept above their MICs and the concentration of the fluoroquinolone is above its MPC, three mutations would be required for bacterial growth. As discussed elsewhere (20), the key to preventing resistance from arising in the dual-drug situation is to have the pharmacokinetic profiles of the two compounds match such that no time exists when the concentration of only one compound is above its MIC and below its MPC. We are now examining potential partners for C-8-methoxy fluoroquinolones to create a highly effective combination therapy for the treatment of infections caused by strains of M. tuberculosis that are already resistant to isoniazid and rifampin.


    ACKNOWLEDGMENTS

We thank John Domagala, Marila Gennaro, Sam Kayman, and Tao Lu for critical comments on the manuscript. We also thank John Domagala and Glenn Tillotson for supplying fluoroquinolones.

The work was supported by grant AI35257 from the National Institutes of Health.


    ADDENDUM IN PROOF

MIC99 and MPC of PD161148 were 0.06 and 2.3 µg/ml, respectively, for the laboratory strain H37Rv.


    FOOTNOTES

* Corresponding author. Mailing address: Public Health Research Institute, 455 First Ave., New York, NY 10016. Phone: (212) 578-0830. Fax: (212) 578-0804. E-mail: drlica{at}phri.nyu.edu.

dagger Publication 69 of the PHRI TB Center.


    REFERENCES
Top
Abstract
Text
References

1. Acocella, G., R. Conti, M. Luisetti, E. Pozzi, and C. Grassi. 1985. Pharmacokinetic studies on antituberculosis regimens in humans. Am. Rev. Respir. Dis. 132:510-515[Medline].
2. Acocella, G., A. Nonis, G. Perna, E. Patane, G. Gialdroni-Grassi, and C. Grassi. 1988. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Am. Rev. Respir. Dis. 138:886-890[Medline].
3. Bifani, P., B. Mathema, Z. Liu, S. Moghazeh, B. Shopsin, B. Tempalski, J. Driscoll, R. Frothingham, J. Musser, P. Alcabes, and B. Kreiswirth. 1999. Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. JAMA 282:2321-2327[Abstract/Free Full Text].
4. Black, H. R., R. S. Griffith, and A. M. Peabody. 1966. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann. N. Y. Acad. Sci. 135:974-982[Medline].
5. Cabana, B., and J. Taggart. 1973. Comparative pharmacokinetics of BB-KS and kanamycin in dogs and humans. Antimicrob. Agents Chemother. 3:478-483[Abstract/Free Full Text].
6. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on bacterial growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984[Abstract/Free Full Text].
7. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758[Abstract/Free Full Text].
8. Harris, H. W. 1995. Chemotherapy of tuberculosis: the beginning, p. 745-749. In W. N. Rom, and S. M. Garay (ed.), Tuberculosis. Little, Brown & Co., Boston, Mass.
9. Israel, D., G. Gillum, M. Turik, K. Harvey, J. Ford, H. Dalton, M. Towle, R. Echols, A. Heller, and R. Polk. 1993. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother. 37:2193-2199[Abstract/Free Full Text].
10. Jacobs, W. R., G. V. Kalpana, J. D. Cirillo, L. Pascopella, S. B. Snapper, R. A. Udani, W. Jones, R. G. Barletta, and B. R. Bloom. 1991. Genetic systems in mycobacteria. Methods Enzymol. 204:537-555[Medline].
11. Kreiswirth, B., and A. Moss. 1995. Genotyping multidrug-resistant M. tuberculosis in New York City, p. 199-209. In W. N. Rom, and S. M. Garay (ed.), Tuberculosis. Little, Brown & Co., Boston, Mass.
12. Levy, S. B. 1998. Multidrug resistance---a sign of the times. N. Engl. J. Med. 338:1376-1378[Free Full Text].
13. Lu, T., X. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activity by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974[Abstract/Free Full Text].
14. Montay, G. 1996. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J. Antimicrob. Chemother. 37(Suppl. A):27-39.
15. Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640[Abstract].
16. Sreevatsan, S., X. Pan, K. Stockbauer, N. Connell, B. Kreiswirth, T. Whittam, and J. M. Musser. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. USA 94:9869-9874[Abstract/Free Full Text].
17. Sullivan, J. T., M. Woodruff, J. Lettieri, V. Agarwal, G. J. Krol, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797[Abstract/Free Full Text].
18. van Embden, J. D., M. D. Cave, J. T. Crawford, J. W. Dale, K. E. Eisenach, B. Gicquel, P. Hermans, C. Martin, R. McAdam, T. M. Shinnick, and P. M. Small. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31:406-409[Abstract/Free Full Text].
19. Zhao, B.-Y., R. Pine, J. Domagala, and K. Drlica. 1999. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob. Agents Chemother. 43:661-666[Abstract/Free Full Text].
20. Zhao, X., and K. Drlica. A general strategy for restricting the selection of antibiotic-resistant mutants derived from fluoroquinolone studies. Clin. Infect. Dis., in press.
21. Zhao, X., J.-Y. Wang, C. Xu, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 1998. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. 42:956-958[Abstract/Free Full Text].
22. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996[Abstract/Free Full Text].
22a. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. Musser, and K. Drlica. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis., in press.
23. Zitkova, L., and J. Tousek. 1974. Pharmacokinetics of cycloserine and terizidone. Chemotherapy (Basel) 20:18-28.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2581-2584, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Udekwu, K. I., Parrish, N., Ankomah, P., Baquero, F., Levin, B. R. (2009). Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63: 745-757 [Abstract] [Full Text]  
  • Almeida, D., Nuermberger, E., Tyagi, S., Bishai, W. R., Grosset, J. (2007). In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 51: 4261-4266 [Abstract] [Full Text]  
  • Ferran, A., Dupouy, V., Toutain, P.-L., Bousquet-Melou, A. (2007). Influence of Inoculum Size on the Selection of Resistant Mutants of Escherichia coli in Relation to Mutant Prevention Concentrations of Marbofloxacin. Antimicrob. Agents Chemother. 51: 4163-4166 [Abstract] [Full Text]  
  • Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., Drusano, G. L. (2007). Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin. Antimicrob. Agents Chemother. 51: 3781-3788 [Abstract] [Full Text]  
  • Gumbo, T., Louie, A., Liu, W., Brown, D., Ambrose, P. G., Bhavnani, S. M., Drusano, G. L. (2007). Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations. Antimicrob. Agents Chemother. 51: 2329-2336 [Abstract] [Full Text]  
  • Malik, M., Drlica, K. (2006). Moxifloxacin Lethality against Mycobacterium tuberculosis in the Presence and Absence of Chloramphenicol.. Antimicrob. Agents Chemother. 50: 2842-2844 [Abstract] [Full Text]  
  • Marcusson, L. L., Olofsson, S. K., Lindgren, P. K., Cars, O., Hughes, D. (2005). Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55: 938-943 [Abstract] [Full Text]  
  • Malik, M., Lu, T., Zhao, X., Singh, A., Hattan, C. M., Domagala, J., Kerns, R., Drlica, K. (2005). Lethality of Quinolones against Mycobacterium smegmatis in the Presence or Absence of Chloramphenicol. Antimicrob. Agents Chemother. 49: 2008-2014 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Konstantinides, G. N., Rotschafer, J. C. (2005). Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens. Antimicrob. Agents Chemother. 49: 1633-1635 [Abstract] [Full Text]  
  • Li, X., Mariano, N., Rahal, J. J., Urban, C. M., Drlica, K. (2004). Quinolone-Resistant Haemophilus influenzae: Determination of Mutant Selection Window for Ciprofloxacin, Garenoxacin, Levofloxacin, and Moxifloxacin. Antimicrob. Agents Chemother. 48: 4460-4462 [Abstract] [Full Text]  
  • Smith, H. J., Walters, M., Hisanaga, T., Zhanel, G. G., Hoban, D. J. (2004). Mutant Prevention Concentrations for Single-Step Fluoroquinolone-Resistant Mutants of Wild-Type, Efflux-Positive, or ParC or GyrA Mutation-Containing Streptococcus pneumoniae Isolates. Antimicrob. Agents Chemother. 48: 3954-3958 [Abstract] [Full Text]  
  • Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Lu, T., Drlica, K. (2003). In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028 [Abstract] [Full Text]  
  • Smith, H. J., Hoban, D. J., Zhanel, G. G. (2003). Reply. J Antimicrob Chemother 52: 732-733 [Full Text]  
  • Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Li, X., Hansen, G., Blondeau, J., Drlica, K. (2003). Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 52: 61-64 [Abstract] [Full Text]  
  • Smith, H. J., Nichol, K. A., Hoban, D. J., Zhanel, G. G. (2003). Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother 51: 1323-1325 [Full Text]  
  • Kishii, R., Takei, M., Fukuda, H., Hayashi, K., Hosaka, M. (2003). Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 77-81 [Abstract] [Full Text]  
  • Alvirez-Freites, E. J., Carter, J. L., Cynamon, M. H. (2002). In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46: 1022-1025 [Abstract] [Full Text]  
  • Gillespie, S. H. (2002). Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective. Antimicrob. Agents Chemother. 46: 267-274 [Full Text]  
  • Montero, C., Mateu, G., Rodriguez, R., Takiff, H. (2001). Intrinsic Resistance of Mycobacteriumsmegmatis to Fluoroquinolones May Be Influenced by New Pentapeptide Protein MfpA. Antimicrob. Agents Chemother. 45: 3387-3392 [Abstract] [Full Text]  
  • Blondeau, J. M., Zhao, X., Hansen, G., Drlica, K. (2001). Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 433-438 [Abstract] [Full Text]  
  • Sindelar, G., Zhao, X., Liew, A., Dong, Y., Lu, T., Zhou, J., Domagala, J., Drlica, K. (2000). Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria. Antimicrob. Agents Chemother. 44: 3337-3343 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»